<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00222482</url>
  </required_header>
  <id_info>
    <org_study_id>0306M49703</org_study_id>
    <secondary_id>M009946</secondary_id>
    <nct_id>NCT00222482</nct_id>
  </id_info>
  <brief_title>Depakote ER in Borderline Personality Disorder</brief_title>
  <official_title>A Double-Blind and Placebo Controlled Assessment of Depakote ER in Borderline Personality Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Minnesota - Clinical and Translational Science Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Schulz, S. Charles, M.D.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Minnesota - Clinical and Translational Science Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study examines the effect of Depakote ER versus placebo in a randomized trial of
      borderline personality disorder. Patients all participate in DBT therapy and those who are
      not responsive are assigned to either Depakote ER or placebo for up to 12 weeks. Borderline
      Personality Symtoms are measured and side-effects are assessed.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2003</start_date>
  <completion_date type="Actual">September 2005</completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Symptom Checklist 90</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Barratt Impulsivity Scale</measure>
  </secondary_outcome>
  <enrollment>15</enrollment>
  <condition>Borderline Personality Disorder</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Depakote ER</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:Male or female patients with the diagnosis of borderline personality
        disorder between the ages of 21 adn 55 years old. Must be in good physical health -

        Exclusion Criteria:Major psychiatric illness on Axis I - schizophrenia or bipolar disorder.
        May not have current MDD. May not be dependent on illicit substances or alcohol.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sellamnn C Schulz, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Psychiatry, University of Minnesota Medical School</affiliation>
  </overall_official>
  <reference>
    <citation>Schulz SC, Camlin KL, Berry SA, Jesberger JA. Olanzapine safety and efficacy in patients with borderline personality disorder and comorbid dysthymia. Biol Psychiatry. 1999 Nov 15;46(10):1429-35.</citation>
    <PMID>10578457</PMID>
  </reference>
  <verification_date>August 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 14, 2005</study_first_submitted>
  <study_first_submitted_qc>September 14, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2005</study_first_posted>
  <last_update_submitted>August 8, 2007</last_update_submitted>
  <last_update_submitted_qc>August 8, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 9, 2007</last_update_posted>
  <keyword>Borderline Personality Disorder</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Personality Disorders</mesh_term>
    <mesh_term>Borderline Personality Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Valproic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

